Stay updated on Azacitidine + Pembrolizumab in AML Clinical Trial
Sign up to get notified when there's something new on the Azacitidine + Pembrolizumab in AML Clinical Trial page.

Latest updates to the Azacitidine + Pembrolizumab in AML Clinical Trial page
- Check3 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3.SummaryDifference0.1%

- Check46 days agoChange DetectedSite revision label updated from v3.4.2 to v3.4.3 in the page header/footer.SummaryDifference0.1%

- Check68 days agoChange DetectedRevision: v3.4.2 was applied, replacing the previous v3.4.1. No substantive study information or user-facing content was changed.SummaryDifference0.1%

- Check75 days agoChange DetectedPage revision updated from v3.4.0 to v3.4.1, which does not alter the study details, inclusion criteria, or outcome measures. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check89 days agoChange DetectedMinor UI/text updates: Show glossary and Hide glossary controls were added, along with a new 'Last Update Submitted that Met QC Criteria' label and a Revision: v3.4.0 tag. Wording and capitalization tweaks were made to 'No FEAR Act Data' and 'Last Update Submitted that met QC Criteria'.SummaryDifference0.3%

Stay in the know with updates to Azacitidine + Pembrolizumab in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Azacitidine + Pembrolizumab in AML Clinical Trial page.